A
917.93
11.19 (1.23%)
| Penutupan Terdahulu | 906.74 |
| Buka | 910.96 |
| Jumlah Dagangan | 354,775 |
| Purata Dagangan (3B) | 368,435 |
| Modal Pasaran | 57,165,234,176 |
| Harga / Pendapatan (P/E TTM) | 39.26 |
| Harga / Pendapatan (P/E Ke hadapan) | 32.05 |
| Harga / Jualan (P/S) | 16.46 |
| Harga / Buku (P/B) | 9.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | 40.26% |
| Margin Operasi (TTM) | 17.50% |
| EPS Cair (TTM) | 16.39 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 95.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.71% |
| Nisbah Semasa (MRQ) | 7.29 |
| Aliran Tunai Operasi (OCF TTM) | -82.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -143.39 M |
| Pulangan Atas Aset (ROA TTM) | -0.21% |
| Pulangan Atas Ekuiti (ROE TTM) | 17.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | argenx SE | Menaik | Menaik |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Institusi | 55.54% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1,146.00 (TD Cowen, 24.85%) | Beli |
| Median | 930.00 (1.32%) | |
| Rendah | 860.00 (RBC Capital, -6.31%) | Beli |
| Purata | 991.64 (8.03%) | |
| Jumlah | 11 Beli | |
| Harga Purata @ Panggilan | 836.57 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 04 Dec 2025 | 1,110.00 (20.92%) | Beli | 915.97 |
| 01 Oct 2025 | 1,040.00 (13.30%) | Beli | 767.33 | |
| Citigroup | 17 Nov 2025 | 1,124.00 (22.45%) | Beli | 929.61 |
| Wedbush | 14 Nov 2025 | 1,000.00 (8.94%) | Beli | 907.98 |
| 13 Oct 2025 | 880.00 (-4.13%) | Beli | 799.56 | |
| JP Morgan | 07 Nov 2025 | 925.00 (0.77%) | Beli | 854.65 |
| Piper Sandler | 04 Nov 2025 | 930.00 (1.31%) | Beli | 831.48 |
| Evercore ISI Group | 31 Oct 2025 | 910.00 (-0.86%) | Beli | 818.50 |
| HC Wainwright & Co. | 31 Oct 2025 | 915.00 (-0.32%) | Beli | 818.50 |
| RBC Capital | 31 Oct 2025 | 860.00 (-6.31%) | Beli | 818.50 |
| TD Cowen | 31 Oct 2025 | 1,146.00 (24.85%) | Beli | 818.50 |
| Guggenheim | 18 Sep 2025 | 1,070.00 (16.57%) | Beli | 731.77 |
| Truist Securities | 15 Sep 2025 | 918.00 (0.01%) | Beli | 756.83 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2025 | Pengumuman | argenx Announces Results of Extraordinary General Meeting of Shareholders |
| 30 Oct 2025 | Pengumuman | argenx Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 29 Oct 2025 | Pengumuman | argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients |
| 23 Oct 2025 | Pengumuman | argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025 |
| 15 Oct 2025 | Pengumuman | argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session |
| 03 Oct 2025 | Pengumuman | argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |